SunTen Phytotech has 5 ongoing product pipelines under development for specific disease populations that are of unmet medical demand. Our strategic plans and risk factors for the development of these pipelines are aligned to be of the same importance. As a result, we focus on developing botanical drug candidates from these product pipelines for both therapeutic and health promoting uses. Having vast amount of experience working with domestic as well as multi-national drug companies, we welcome all interested parties to work with us in order to bring in new hopes into medical therapy, providing great benefit to humankind. We are currently seeking a qualified regional or global biotech/pharmaceutical company for product licensing, development, and commercialization on the following 5 projects.

(1) SB221 is under Phase II clinical trials for vascular endothelial dysfunction-related diseases, such as atherosclerosis and hypertension. (2) STA36 is a botanical composition under developed as an adjuvant therapy for chronic allergic asthma. Exploratory Phase II clinical trial demonstrated safety and efficacy of STA36 as a supporting treatment for persistent, mild-to-moderate asthma. (3) STD052, partially purified herbal extract, is under development for constipation, cholesterol lowering, and obesity. Active components, such as STD07, were purified and now under preclinical development for gastrointestinal disorders. (4) STD06, an active compound purified from a topical herbal medicine for various skin diseases, such as dermatitis and wound healing.